Acral erythema has been reported in patients receiving sustained dosing (or those who could use prolonged exposure) of the cytotoxic drugs fluorouracil, capecitabine, cytarabine, sorafenib, sunitinib, and pegylated liposomal doxorubicin.
Tingling and/or numbness (aka paresthesias) in the palms and soles are the first symptoms, which then evolve into painful well-demarcated symmetrical swelling and red plaques, followed by peeling and symptom resolution.
Acral erythema, with similar clinical and histological features, can also occur after bone marrow transplant due to dermatologic manifestations of graft vs. host disease.
Symptoms generally resolve 1 to 2 weeks after discontinuing chemotherapy. Results from small clinical studies suggest that corticosteroids may be helpful in relieving symptoms, and that frequent applications of emollients to the hands and feet may help prevent the disorder. The offending anticancer drug may be reintroduced at lower doses once the side effects have abated.
Acral erythema is an adverse drug reaction to chemotherapy that can occur days to months after a patient begins treatment and results in reddening, swelling and desquamation of the skin, often of the palms and soles. The syndrome is also referred to as hand-foot syndrome, palmar-plantar erythrodysesthesia, and Burgdorf’s reaction.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Targeting AR Mutations Promising in Metastatic Prostate Cancer
- GUCS 2017: Early Immunotherapy Discontinuation in mRCC
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Myalgia-arthralgia Syndrome Associated With Taxanes in Patients with Breast Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|